Clinical utility of chromosomal microarray analysis in prenatal diagnosis

Report of first 6 months in clinical practice

Susan D. Klugman, Barrie Suskin, Brianna L. Spencer, Pe'er Dar, Komal Bajaj, Judith F. Powers, Julie Reichling, David Wasserman, Siobhan M. Dolan, Irwin R. Merkatz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: We studied the clinical utility of chromosomal microarray analysis (CMA) in prenatal diagnosis in a clinical setting in New York City. Methods: Our center began offering CMA to pregnant women undergoing invasive diagnostic procedures for an abnormal structural finding on ultrasound, maternal age of 35 years or older, or elevated risk on aneuploidy screening, beginning March 2012. Our first six months experience is reported. Results: Benign familial variants were the most common finding (16/22 fetuses). Variants of uncertain significance were frequent, especially when fathers were not available for testing (4/22 fetuses). Most patients undertook CMA as part of evaluation of an ultrasound anomaly (52%). One patient terminated a pregnancy based on an ultrasound finding in the setting of a benign familial variant on CMA, and a second terminated a pregnancy based on a copy number variant identified on CMA. Conclusion: For CMA to be maximally useful in prenatal diagnosis, parental DNA samples as well as robust datasets to provide predictive phenotypic information are required. The most common reason for undertaking CMA was to evaluate an ultrasound anomaly, and benign familial variants were a common finding. Genetic services are required to provide pre- and post-test genetic counseling and help families interpret results.

Original languageEnglish (US)
Pages (from-to)1333-1338
Number of pages6
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume27
Issue number13
DOIs
StatePublished - 2014

Fingerprint

Microarray Analysis
Prenatal Diagnosis
Fetus
Genetic Services
Pregnancy
Genetic Counseling
Maternal Age
Aneuploidy
Fathers
Pregnant Women
DNA

Keywords

  • Amniocentesis
  • Chromosomal microarray analysis
  • Genetic counseling
  • Prenatal diagnosis
  • Variants of uncertain significance

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Clinical utility of chromosomal microarray analysis in prenatal diagnosis : Report of first 6 months in clinical practice. / Klugman, Susan D.; Suskin, Barrie; Spencer, Brianna L.; Dar, Pe'er; Bajaj, Komal; Powers, Judith F.; Reichling, Julie; Wasserman, David; Dolan, Siobhan M.; Merkatz, Irwin R.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 27, No. 13, 2014, p. 1333-1338.

Research output: Contribution to journalArticle

@article{b6c41a79240e49aebb7b9bf1766e41ac,
title = "Clinical utility of chromosomal microarray analysis in prenatal diagnosis: Report of first 6 months in clinical practice",
abstract = "Objective: We studied the clinical utility of chromosomal microarray analysis (CMA) in prenatal diagnosis in a clinical setting in New York City. Methods: Our center began offering CMA to pregnant women undergoing invasive diagnostic procedures for an abnormal structural finding on ultrasound, maternal age of 35 years or older, or elevated risk on aneuploidy screening, beginning March 2012. Our first six months experience is reported. Results: Benign familial variants were the most common finding (16/22 fetuses). Variants of uncertain significance were frequent, especially when fathers were not available for testing (4/22 fetuses). Most patients undertook CMA as part of evaluation of an ultrasound anomaly (52{\%}). One patient terminated a pregnancy based on an ultrasound finding in the setting of a benign familial variant on CMA, and a second terminated a pregnancy based on a copy number variant identified on CMA. Conclusion: For CMA to be maximally useful in prenatal diagnosis, parental DNA samples as well as robust datasets to provide predictive phenotypic information are required. The most common reason for undertaking CMA was to evaluate an ultrasound anomaly, and benign familial variants were a common finding. Genetic services are required to provide pre- and post-test genetic counseling and help families interpret results.",
keywords = "Amniocentesis, Chromosomal microarray analysis, Genetic counseling, Prenatal diagnosis, Variants of uncertain significance",
author = "Klugman, {Susan D.} and Barrie Suskin and Spencer, {Brianna L.} and Pe'er Dar and Komal Bajaj and Powers, {Judith F.} and Julie Reichling and David Wasserman and Dolan, {Siobhan M.} and Merkatz, {Irwin R.}",
year = "2014",
doi = "10.3109/14767058.2013.858243",
language = "English (US)",
volume = "27",
pages = "1333--1338",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "13",

}

TY - JOUR

T1 - Clinical utility of chromosomal microarray analysis in prenatal diagnosis

T2 - Report of first 6 months in clinical practice

AU - Klugman, Susan D.

AU - Suskin, Barrie

AU - Spencer, Brianna L.

AU - Dar, Pe'er

AU - Bajaj, Komal

AU - Powers, Judith F.

AU - Reichling, Julie

AU - Wasserman, David

AU - Dolan, Siobhan M.

AU - Merkatz, Irwin R.

PY - 2014

Y1 - 2014

N2 - Objective: We studied the clinical utility of chromosomal microarray analysis (CMA) in prenatal diagnosis in a clinical setting in New York City. Methods: Our center began offering CMA to pregnant women undergoing invasive diagnostic procedures for an abnormal structural finding on ultrasound, maternal age of 35 years or older, or elevated risk on aneuploidy screening, beginning March 2012. Our first six months experience is reported. Results: Benign familial variants were the most common finding (16/22 fetuses). Variants of uncertain significance were frequent, especially when fathers were not available for testing (4/22 fetuses). Most patients undertook CMA as part of evaluation of an ultrasound anomaly (52%). One patient terminated a pregnancy based on an ultrasound finding in the setting of a benign familial variant on CMA, and a second terminated a pregnancy based on a copy number variant identified on CMA. Conclusion: For CMA to be maximally useful in prenatal diagnosis, parental DNA samples as well as robust datasets to provide predictive phenotypic information are required. The most common reason for undertaking CMA was to evaluate an ultrasound anomaly, and benign familial variants were a common finding. Genetic services are required to provide pre- and post-test genetic counseling and help families interpret results.

AB - Objective: We studied the clinical utility of chromosomal microarray analysis (CMA) in prenatal diagnosis in a clinical setting in New York City. Methods: Our center began offering CMA to pregnant women undergoing invasive diagnostic procedures for an abnormal structural finding on ultrasound, maternal age of 35 years or older, or elevated risk on aneuploidy screening, beginning March 2012. Our first six months experience is reported. Results: Benign familial variants were the most common finding (16/22 fetuses). Variants of uncertain significance were frequent, especially when fathers were not available for testing (4/22 fetuses). Most patients undertook CMA as part of evaluation of an ultrasound anomaly (52%). One patient terminated a pregnancy based on an ultrasound finding in the setting of a benign familial variant on CMA, and a second terminated a pregnancy based on a copy number variant identified on CMA. Conclusion: For CMA to be maximally useful in prenatal diagnosis, parental DNA samples as well as robust datasets to provide predictive phenotypic information are required. The most common reason for undertaking CMA was to evaluate an ultrasound anomaly, and benign familial variants were a common finding. Genetic services are required to provide pre- and post-test genetic counseling and help families interpret results.

KW - Amniocentesis

KW - Chromosomal microarray analysis

KW - Genetic counseling

KW - Prenatal diagnosis

KW - Variants of uncertain significance

UR - http://www.scopus.com/inward/record.url?scp=84905454463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905454463&partnerID=8YFLogxK

U2 - 10.3109/14767058.2013.858243

DO - 10.3109/14767058.2013.858243

M3 - Article

VL - 27

SP - 1333

EP - 1338

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 13

ER -